Is MRVI or NAMS more undervalued in 2026?

CirclFi compares Maravai LifeSciences Holdings, (MRVI) and NewAmsterdam Pharma Company N.V (NAMS) using 13 institutional-grade valuation models. MRVI has a Quality of Company score of 6.4/10 while NAMS scores 2.3/10.

Which is a better buy — MRVI or NAMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MRVI and NAMS valuations compare?

MRVI at $4.64 and NAMS at $35.42 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MRVI vs NAMS Valuation Comparison 2026 — Intrinsic Value Analysis

MRVI

Biotechnology

Maravai LifeSciences Holdings,

Quality

6.4

out of 10

Value Trap

—

Price

$4.64

Last close

Models

12/13

Active

NAMS

Biotechnology

NewAmsterdam Pharma Company N.V

Quality

2.3

out of 10

Value Trap

—

Price

$35.42

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MRVI Fair Value	MRVI Upside	NAMS Fair Value	NAMS Upside
Bayesian DCF	Intrinsic	$15.68	+238.0%	$7.68	-78.3%
Earnings Power Value	Intrinsic	$0.05	-98.9%	$18.09	-39.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MRVI vs NAMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MRVI vs NAMS — Which Stock Is More Undervalued?

MRVI scores higher with a 6.4/10 quality rating vs NAMS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Maravai LifeSciences Holdings, (MRVI) and NewAmsterdam Pharma Company N.V (NAMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MRVI currently trades at $4.64 with a QOC of 6.4/10, while NAMS trades at $35.42 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).